The global polyclonal antibodies market is valued at approximately USD 1.68 billion in 2024 and is expected to grow to USD 1.76 billion in 2025, with a projected reach of around USD 2.74 billion by 2034. This growth represents a steady annual expansion of 5.04% from 2025 to 2034. The rising number of diseases and the increasing demand for therapeutic options are key drivers of this market’s growth.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5388
Polyclonal antibodies (pAbs) are produced by B cells in the body’s adaptive immune system. Unlike monoclonal antibodies (mAbs), which target a single epitope on an antigen, polyclonal antibodies recognize multiple epitopes on a single antigen. These antibodies are vital in research, diagnostics, and treatment. They are used in immunodiagnostics, food quality control, and veterinary and human medicine for regular diagnostics. Additionally, polyclonal antibodies have therapeutic applications and may possess anti-inflammatory or immunomodulatory effects.
Recent advancements are accelerating the use of polyclonal antibodies in various fields. In November 2024, Sanofi announced an investment of €40 million (US$42 million) to enhance its bioproduction facility in Lyon, France. A portion of this funding will be dedicated to research and production of Thymoglobulin (anti-thymocyte globulin [rabbit]), a polyclonal antibody used in transplant care.
Additionally, in October 2024, EQT Life Sciences revealed the acquisition of ATB Therapeutics by its LSP 7 fund. The goal of this €54 million Series A fundraising is to accelerate the clinical development of novel therapeutic antibodies, advancing the company’s ATBioFarm technology.
AI integration is playing a transformative role in the development of polyclonal antibodies. AI-driven methods help predict the potential of antibodies to penetrate cells and enhance their properties such as toxicity, immunogenicity, solubility, and half-life in the body. This technology is significantly reducing the time and costs associated with drug development.
A notable example is Antiverse, a techbio startup that utilizes AI to design antibodies for challenging targets. In October 2024, the company closed a €4.2 million seed funding round, bringing its total equity financing to €8.6 million. This investment supports their mission to revolutionize antibody design through generative AI.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/polyclonal-antibodies-market-sizing
Access exclusive insight now @ https://www.towardshealthcare.com/price/5388
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
The global pharma CRO services market is on a solid growth path. It’s expected to jump from USD 36.66 billion… Read More
The use of Artificial Intelligence (AI) in mental health care is growing fast. In 2024, this market was worth about… Read More
The global cancer vaccines market is on a strong growth path. It's expected to expand from $11.38 billion in 2025… Read More
The global bioprocess containers market is on a major growth path. Valued at around $3.12 billion in 2024, it’s expected… Read More
The world is moving towards personalized healthcare, and patient-centric apps are at the forefront of this shift. In 2024, the… Read More
📊 Market Snapshot The global flow cytometry services market is witnessing impressive growth. It was valued at USD 3.37 billion… Read More